Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ustekinumab biosimilar - DM Bio

Next Previous
Drug Profile

Ustekinumab biosimilar - DM Bio

Alternative Names: Absimky; DA 3115; DMB 3115; Imuldosa

Latest Information Update: 19 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Socio Holdings; Dong-A ST; Meiji Seika Pharma
  • Developer Dong-A Socio Holdings; Intas Pharmaceuticals; Meiji Seika Pharma
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Psoriasis

Highest Development Phases

  • Registered Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
  • Preregistration Immunological disorders

Most Recent Events

  • 16 Dec 2024 Registered for Crohn's disease (Treatment-experienced) in European Union, Iceland, Iceland, Norway, Liechtenstein (SC)
  • 16 Dec 2024 Registered for Plaque psoriasis (In adolescents, In children, In adults) in European Union, Iceland, Norway, Liechtenstein (SC)
  • 16 Dec 2024 Registered for Psoriatic arthritis (Treatment-experienced) in European Union, Iceland, Norway, Liechtenstein (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top